DK3267984T3 - Forbindelserne 1,2,4-oxadiazol og thoadiazol som immunmodulatorer - Google Patents
Forbindelserne 1,2,4-oxadiazol og thoadiazol som immunmodulatorer Download PDFInfo
- Publication number
- DK3267984T3 DK3267984T3 DK16761169.8T DK16761169T DK3267984T3 DK 3267984 T3 DK3267984 T3 DK 3267984T3 DK 16761169 T DK16761169 T DK 16761169T DK 3267984 T3 DK3267984 T3 DK 3267984T3
- Authority
- DK
- Denmark
- Prior art keywords
- thoadiazole
- oxadiazole
- compounds
- immune modulators
- modulators
- Prior art date
Links
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1180CH2015 | 2015-03-10 | ||
| IN1178CH2015 | 2015-03-10 | ||
| PCT/IB2016/051266 WO2016142833A1 (en) | 2015-03-10 | 2016-03-07 | 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3267984T3 true DK3267984T3 (da) | 2022-03-07 |
Family
ID=56879282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16761169.8T DK3267984T3 (da) | 2015-03-10 | 2016-03-07 | Forbindelserne 1,2,4-oxadiazol og thoadiazol som immunmodulatorer |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10781189B2 (da) |
| EP (2) | EP3267984B1 (da) |
| JP (5) | JP6815686B2 (da) |
| KR (1) | KR102708045B1 (da) |
| CN (4) | CN114159430B (da) |
| AU (3) | AU2016230793B2 (da) |
| CA (2) | CA3220902A1 (da) |
| CU (1) | CU24509B1 (da) |
| CY (1) | CY1125161T1 (da) |
| DK (1) | DK3267984T3 (da) |
| EA (1) | EA034708B1 (da) |
| ES (1) | ES2907988T3 (da) |
| HR (1) | HRP20220258T1 (da) |
| HU (1) | HUE058274T2 (da) |
| IL (3) | IL305546A (da) |
| LT (1) | LT3267984T (da) |
| MX (2) | MX389392B (da) |
| MY (1) | MY196130A (da) |
| NZ (1) | NZ734650A (da) |
| PH (1) | PH12017501454A1 (da) |
| PL (1) | PL3267984T3 (da) |
| PT (1) | PT3267984T (da) |
| RS (1) | RS62960B1 (da) |
| SG (2) | SG10202108921VA (da) |
| SI (1) | SI3267984T1 (da) |
| SM (1) | SMT202200163T1 (da) |
| WO (1) | WO2016142833A1 (da) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2893597C (en) | 2012-12-07 | 2021-06-29 | Chemocentryx, Inc. | Diazole lactams |
| ES2675027T3 (es) | 2013-09-06 | 2018-07-05 | Aurigene Discovery Technologies Limited | Derivados de 1,2,4-oxadiazol como inmunomoduladores |
| DK3267984T3 (da) * | 2015-03-10 | 2022-03-07 | Aurigene Discovery Tech Ltd | Forbindelserne 1,2,4-oxadiazol og thoadiazol som immunmodulatorer |
| PL3439653T3 (pl) | 2016-04-07 | 2021-07-05 | Chemocentryx, Inc. | Zmniejszenie obciążenia guzem przez podawanie antagonistów ccr1 w skojarzeniu z inhibitorami pd-1 lub inhibitorami pd-l1 |
| WO2018047139A1 (en) * | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Compounds as modulators of tigit signalling pathway |
| WO2018051254A1 (en) * | 2016-09-14 | 2018-03-22 | Aurigene Discovery Technologies Limited | Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators |
| WO2018071849A2 (en) | 2016-10-14 | 2018-04-19 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| MY205585A (en) * | 2016-10-20 | 2024-10-28 | Aurigene Oncology Ltd | Dual inhibitors of vista and pd-1 pathways |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| EP3567049A4 (en) | 2016-12-28 | 2020-08-26 | Green Cross Lab Cell Corporation | CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME |
| CN108395443B (zh) * | 2017-02-04 | 2021-05-04 | 广州丹康医药生物有限公司 | 抑制程序性死亡受体配体1的环状化合物及其用途 |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| WO2018196768A1 (zh) * | 2017-04-26 | 2018-11-01 | 南京圣和药业股份有限公司 | 作为pd-l1抑制剂的杂环类化合物 |
| CN109096219B (zh) * | 2017-06-20 | 2023-03-21 | 广州丹康医药生物有限公司 | 一种新型抗pd-l1化合物、其应用及含其的组合物 |
| WO2019061324A1 (en) * | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
| SG11202003081WA (en) | 2017-10-11 | 2020-05-28 | Aurigene Discovery Tech Ltd | Crystalline forms of 3-substituted 1,2,4-oxadiazole |
| BR112020008537A2 (pt) * | 2017-11-03 | 2020-10-06 | Aurigene Discovery Technologies Limited | inibidores duplos de vias da tim-3 e da pd-1 |
| EA202090749A1 (ru) | 2017-11-06 | 2020-08-19 | Ориджен Дискавери Текнолоджис Лимитед | Способы совместной терапии для иммуномодуляции |
| JP7544598B2 (ja) | 2017-11-10 | 2024-09-03 | アーモ・バイオサイエンシーズ・インコーポレイテッド | 免疫チェックポイント経路阻害剤と併用したインターロイキン－１０の組成物および使用方法 |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| WO2019098682A1 (ko) | 2017-11-14 | 2019-05-23 | 앱클론(주) | 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체 |
| CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
| CA3084582A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| KR20250057146A (ko) * | 2018-01-12 | 2025-04-28 | 오리진 온콜로지 리미티드 | Cd47 신호전달 경로의 저해제로서의 1,2,4-옥사다이아졸 화합물 |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2019165374A1 (en) | 2018-02-26 | 2019-08-29 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
| MX2020009443A (es) * | 2018-03-14 | 2021-01-08 | Aurigene Discovery Tech Ltd | Método de modulación de las vías de señalización de tigit y pd-1 mediante el uso de compuestos de 1,2,4-oxadiazol. |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| CN112041311B (zh) | 2018-04-19 | 2023-10-03 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| CN108586549A (zh) * | 2018-05-31 | 2018-09-28 | 成都市科隆化学品有限公司 | 一种Fmoc-Thr(tBu)-OH的制备方法 |
| TW202017569A (zh) | 2018-05-31 | 2020-05-16 | 美商佩樂敦治療公司 | 用於抑制cd73之組合物及方法 |
| US20210347842A1 (en) | 2018-06-19 | 2021-11-11 | Eli Lilly And Company | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy |
| KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| CN111057069B (zh) * | 2018-10-16 | 2024-01-26 | 武汉光谷通用名药物研究院有限公司 | 一种环状化合物、其应用及组合物 |
| EP3870566A1 (en) | 2018-10-24 | 2021-09-01 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| TWI721624B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| PE20211655A1 (es) | 2018-10-31 | 2021-08-24 | Gilead Sciences Inc | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 |
| EP3876931A1 (en) * | 2018-11-08 | 2021-09-15 | Aurigene Discovery Technologies Limited | Combination of small molecule cd-47 inhibitors with other anti-cancer agents |
| KR20210106531A (ko) | 2018-12-21 | 2021-08-30 | 에임 이뮤노테크 인코포레이티드 | 암 치료를 위한 조성물 및 방법 |
| KR102707808B1 (ko) | 2019-03-07 | 2024-09-19 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭 |
| KR102808642B1 (ko) | 2019-03-07 | 2025-05-14 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭 |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CN111909108B (zh) * | 2019-09-02 | 2023-05-02 | 中国药科大学 | 联苯类化合物及其制备方法和医药用途 |
| KR20250040096A (ko) | 2019-09-30 | 2025-03-21 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 백신 및 hbv를 치료하는 방법 |
| AU2020358726A1 (en) | 2019-10-01 | 2022-04-07 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| ES3022990T3 (en) | 2019-12-06 | 2025-05-29 | Prec Biosciences Inc | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| CA3181538A1 (en) | 2020-05-05 | 2021-11-11 | Teon Therapeutics, Inc. | Cannabinoid receptor type 2 (cb2) modulators and uses thereof |
| CA3204162A1 (en) | 2021-01-11 | 2022-07-14 | Robert Kastelein | Compositions and methods related to receptor pairing |
| KR20240006683A (ko) | 2021-05-13 | 2024-01-15 | 길리애드 사이언시즈, 인코포레이티드 | TLR8 조절 화합물과 항-HBV siRNA 치료제의 조합물 |
| WO2022261310A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
| WO2022261301A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| AU2022297367B2 (en) | 2021-06-23 | 2025-04-10 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7654118B2 (ja) | 2021-06-23 | 2025-03-31 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3226163A1 (en) | 2021-07-14 | 2023-01-19 | Synthekine, Inc. | Methods and compositions for use in cell therapy of neoplastic disease |
| WO2023034530A1 (en) | 2021-09-02 | 2023-03-09 | Teon Therapeutics, Inc. | Methods of improving growth and function of immune cells |
| WO2023081730A1 (en) | 2021-11-03 | 2023-05-11 | Teon Therapeutics, Inc. | 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer |
| WO2023097211A1 (en) | 2021-11-24 | 2023-06-01 | The University Of Southern California | Methods for enhancing immune checkpoint inhibitor therapy |
| EP4554943A1 (en) | 2022-07-14 | 2025-05-21 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1557852A (en) * | 1922-08-15 | 1925-10-20 | Lauerman Clarence Haines | Galvanized-iron ventilator |
| US3227725A (en) | 1962-04-17 | 1966-01-04 | Union Carbide Corp | Certain 3,5-disubstituted 1,2,4-oxadiazole compounds |
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| TW201311B (da) | 1991-06-17 | 1993-03-01 | Hoffmann La Roche | |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| AU1739099A (en) * | 1994-03-08 | 1999-05-20 | American Home Products Corporation | Effector proteins of rapamycin |
| CA2143246C (en) * | 1994-03-16 | 2000-08-22 | Thierry Godel | Imidazodiazepines |
| CN1762381B (zh) | 1997-07-29 | 2012-07-11 | 爱尔康实验室公司 | 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物 |
| JP2002501892A (ja) | 1998-01-29 | 2002-01-22 | セプラコア インコーポレーテッド | 光学的に純粋な（−）−ビュープロピオンの薬学的使用 |
| AU7072700A (en) | 1999-08-23 | 2001-03-19 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| JP2004533226A (ja) | 2001-04-02 | 2004-11-04 | ワイス | Ｂ７−４に対するｐｄ−１、ａレセプター、およびその使用 |
| WO2002086083A2 (en) | 2001-04-20 | 2002-10-31 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| GB0204159D0 (en) | 2002-02-22 | 2002-04-10 | British Biotech Pharm | Metalloproteinase inhibitors |
| CN1665808A (zh) * | 2002-05-06 | 2005-09-07 | 沃泰克斯药物股份有限公司 | 噻二唑或噁二唑及其作为jak蛋白激酶抑制剂的用途 |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| ATE514713T1 (de) | 2002-12-23 | 2011-07-15 | Wyeth Llc | Antikörper gegen pd-1 und ihre verwendung |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| JP2007501799A (ja) | 2003-08-07 | 2007-02-01 | アラーガン、インコーポレイテッド | 眼内に医薬を送達するための組成物ならびにその調製方法および使用方法 |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| AR046787A1 (es) * | 2003-12-05 | 2005-12-21 | Bristol Myers Squibb Co | Agentes antimigrana heterociclicos |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| EP1593671A1 (en) | 2004-03-05 | 2005-11-09 | Graffinity Pharmaceuticals AG | DPP-IV inhibitors |
| US8193359B2 (en) | 2004-12-24 | 2012-06-05 | Prosidion Limited | G-protein coupled receptor agonists |
| NZ563193A (en) | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| US20090170907A1 (en) | 2005-06-06 | 2009-07-02 | Smithkline Beecham Corporation | Chemical Compounds |
| CA2633042A1 (en) | 2005-12-20 | 2007-07-05 | Merck & Co., Inc. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| WO2007095602A2 (en) | 2006-02-15 | 2007-08-23 | Abbott Laboratories | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| US20080021217A1 (en) | 2006-07-20 | 2008-01-24 | Allen Borchardt | Heterocyclic inhibitors of rho kinase |
| KR101430144B1 (ko) | 2006-09-25 | 2014-08-13 | 피티씨 테라퓨틱스, 인크. | 3-[5-(2-플루오로페닐)-[1,2,4]옥사디아졸-3-일]-벤조익 산의 결정형 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| EP2178531A4 (en) | 2007-07-02 | 2012-01-11 | Yu Ming | METHODS AND COMPOSITIONS, TARGETS FOR COMBINED CANCER TREATMENTS |
| US7868001B2 (en) | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
| ATE551342T1 (de) | 2008-02-22 | 2012-04-15 | Irm Llc | Heterocyclische verbindungen und zusammensetzungen als c-kit- und pdgfr- kinasehemmer |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| US20110275673A1 (en) | 2008-09-19 | 2011-11-10 | Yibin Xiang | Inhibitors of sphingosine kinase 1 |
| JP2012507563A (ja) * | 2008-10-30 | 2012-03-29 | エリクシアー ファーマシューティカルズ， インコーポレイテッド | スルホンアミド含有化合物およびその使用 |
| SMT202400136T1 (it) | 2008-12-09 | 2024-05-14 | Hoffmann La Roche | Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| WO2011137587A1 (en) | 2010-05-06 | 2011-11-10 | Hutchison Medipharma Limited | Cytokine inhibitors |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2012129564A2 (en) | 2011-03-24 | 2012-09-27 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Proteasome chymotrypsin-like inhibition using pi-1833 analogs |
| EP2717895A1 (en) | 2011-06-08 | 2014-04-16 | Aurigene Discovery Technologies Limited | Therapeutic compounds for immunomodulation |
| UA111503C2 (uk) | 2011-09-27 | 2016-05-10 | Новартіс Аг | 3-піримідин-4-іл-оксазолідин-2-они як інгібітори мутантної idh |
| HK1205111A1 (en) * | 2011-11-03 | 2015-12-11 | 霍夫曼-拉罗奇有限公司 | 8-fluorophthalazin-1 (2h) - one compounds as inhibitors of btk activity |
| CN104105697B (zh) * | 2011-11-03 | 2016-11-09 | 霍夫曼-拉罗奇有限公司 | 二环哌嗪化合物 |
| BR112014010439A2 (pt) * | 2011-11-03 | 2017-04-18 | F Hoffmann - La Roche Ag | compostos, composição farmacêutica, processo de produção, método de tratamento de uma doença ou distúrbio, métodos, kit e uso de uma composição farmacêutica |
| EP2822957A1 (en) | 2012-03-07 | 2015-01-14 | Aurigene Discovery Technologies Limited | Peptidomimetic compounds as immunomodulators |
| KR20140142736A (ko) | 2012-03-29 | 2014-12-12 | 오리진 디스커버리 테크놀로지스 리미티드 | 인간의 pd1의 bc 루프로부터의 면역조절 사이클릭 화합물 |
| CA3139031A1 (en) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| WO2014059173A2 (en) | 2012-10-10 | 2014-04-17 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| NZ631762A (en) | 2013-01-09 | 2017-02-24 | Gilead Sciences Inc | 5-membered heteroaryls and their use as antiviral agents |
| GEP201706699B (en) | 2013-03-14 | 2017-07-10 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| WO2014147586A1 (en) | 2013-03-22 | 2014-09-25 | Novartis Ag | 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh |
| ES2675027T3 (es) | 2013-09-06 | 2018-07-05 | Aurigene Discovery Technologies Limited | Derivados de 1,2,4-oxadiazol como inmunomoduladores |
| MX2016002971A (es) | 2013-09-06 | 2016-10-07 | Aurigene Discovery Tech Ltd | Derivados de 1,3,4-oxadiazol y 1,3,4-tiadiazol como inmunomoduladores. |
| AU2013400609B9 (en) | 2013-09-13 | 2020-03-05 | Beone Medicines I Gmbh | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
| WO2016073470A1 (en) | 2014-11-04 | 2016-05-12 | The University Of Kansas | Lkb1-ampk activators for therapeutic use in polycystic kidney disease |
| WO2016142852A1 (en) | 2015-03-10 | 2016-09-15 | Aurigene Discovery Technologies Limited | 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators |
| CN107427476A (zh) | 2015-03-10 | 2017-12-01 | 奥瑞基尼探索技术有限公司 | 作为免疫调节剂的3‑取代的‑1,2,4‑噁二唑和噻二唑化合物 |
| DK3267984T3 (da) | 2015-03-10 | 2022-03-07 | Aurigene Discovery Tech Ltd | Forbindelserne 1,2,4-oxadiazol og thoadiazol som immunmodulatorer |
| WO2018047143A1 (en) | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Vista signaling pathway inhibitory compounds useful as immunomodulators |
| MY205585A (en) | 2016-10-20 | 2024-10-28 | Aurigene Oncology Ltd | Dual inhibitors of vista and pd-1 pathways |
| WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
| SG11202003081WA (en) | 2017-10-11 | 2020-05-28 | Aurigene Discovery Tech Ltd | Crystalline forms of 3-substituted 1,2,4-oxadiazole |
| BR112020008537A2 (pt) | 2017-11-03 | 2020-10-06 | Aurigene Discovery Technologies Limited | inibidores duplos de vias da tim-3 e da pd-1 |
| EA202090749A1 (ru) | 2017-11-06 | 2020-08-19 | Ориджен Дискавери Текнолоджис Лимитед | Способы совместной терапии для иммуномодуляции |
-
2016
- 2016-03-07 DK DK16761169.8T patent/DK3267984T3/da active
- 2016-03-07 EA EA201791626A patent/EA034708B1/ru unknown
- 2016-03-07 HR HRP20220258TT patent/HRP20220258T1/hr unknown
- 2016-03-07 AU AU2016230793A patent/AU2016230793B2/en active Active
- 2016-03-07 RS RS20220194A patent/RS62960B1/sr unknown
- 2016-03-07 IL IL305546A patent/IL305546A/en unknown
- 2016-03-07 MY MYPI2017703073A patent/MY196130A/en unknown
- 2016-03-07 US US15/556,800 patent/US10781189B2/en active Active
- 2016-03-07 IL IL254040A patent/IL254040B2/en unknown
- 2016-03-07 SI SI201631482T patent/SI3267984T1/sl unknown
- 2016-03-07 ES ES16761169T patent/ES2907988T3/es active Active
- 2016-03-07 CN CN202111317930.6A patent/CN114159430B/zh active Active
- 2016-03-07 KR KR1020177025706A patent/KR102708045B1/ko active Active
- 2016-03-07 PL PL16761169T patent/PL3267984T3/pl unknown
- 2016-03-07 LT LTEPPCT/IB2016/051266T patent/LT3267984T/lt unknown
- 2016-03-07 CN CN202111317986.1A patent/CN114213356A/zh active Pending
- 2016-03-07 CU CU2017000119A patent/CU24509B1/es unknown
- 2016-03-07 SG SG10202108921VA patent/SG10202108921VA/en unknown
- 2016-03-07 JP JP2017547558A patent/JP6815686B2/ja active Active
- 2016-03-07 CN CN201680014744.6A patent/CN107427477B/zh active Active
- 2016-03-07 EP EP16761169.8A patent/EP3267984B1/en active Active
- 2016-03-07 WO PCT/IB2016/051266 patent/WO2016142833A1/en not_active Ceased
- 2016-03-07 NZ NZ734650A patent/NZ734650A/en unknown
- 2016-03-07 SG SG11201706908PA patent/SG11201706908PA/en unknown
- 2016-03-07 EP EP21209727.3A patent/EP4023645A1/en active Pending
- 2016-03-07 SM SM20220163T patent/SMT202200163T1/it unknown
- 2016-03-07 MX MX2020003735A patent/MX389392B/es unknown
- 2016-03-07 CA CA3220902A patent/CA3220902A1/en active Pending
- 2016-03-07 CN CN202111303250.9A patent/CN114044760A/zh active Pending
- 2016-03-07 PT PT167611698T patent/PT3267984T/pt unknown
- 2016-03-07 MX MX2017011618A patent/MX384444B/es unknown
- 2016-03-07 HU HUE16761169A patent/HUE058274T2/hu unknown
- 2016-03-07 CA CA2979137A patent/CA2979137C/en active Active
-
2017
- 2017-08-11 PH PH12017501454A patent/PH12017501454A1/en unknown
-
2020
- 2020-07-29 JP JP2020128394A patent/JP6937090B2/ja active Active
- 2020-08-01 US US16/945,854 patent/US11465976B2/en active Active
-
2021
- 2021-06-22 AU AU2021204220A patent/AU2021204220B2/en active Active
- 2021-08-27 JP JP2021139182A patent/JP7325483B6/ja active Active
-
2022
- 2022-02-24 CY CY20221100154T patent/CY1125161T1/el unknown
- 2022-10-10 US US17/962,976 patent/US20230110077A1/en not_active Abandoned
-
2023
- 2023-08-01 JP JP2023125731A patent/JP7659015B2/ja active Active
-
2024
- 2024-01-15 AU AU2024200257A patent/AU2024200257A1/en active Pending
-
2025
- 2025-03-26 JP JP2025052596A patent/JP2025114536A/ja active Pending
- 2025-09-04 IL IL323188A patent/IL323188A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3267984T3 (da) | Forbindelserne 1,2,4-oxadiazol og thoadiazol som immunmodulatorer | |
| DK3347472T3 (da) | Sammensætninger som indeholder cyp76ad1- clade polypeptider og anvendelse heraf. | |
| DK3218392T3 (da) | Makrocykliske peptider, der er anvendelige som immunmodulatorer | |
| DK3394033T3 (da) | Heterocykliske forbindelser som immunmodulatorer | |
| LT3230281T (lt) | 1,3-tiazol-2-ilu pakeisti benzamidai | |
| JP2016028081A5 (da) | ||
| DK3328844T3 (da) | 1,3,4-oxadiazolsulfamidderivater som histondeacetylase-6-inhibitor og farmaceutisk sammensætning omfattende samme | |
| JP2016028092A5 (da) | ||
| BR112016018521A2 (pt) | composição, e, kit. | |
| DK3229810T3 (da) | Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler | |
| JP2016065085A5 (da) | ||
| DK3218504T3 (da) | Trisegmenterede arenavira som vaccinevektorer | |
| KR20180084876A (ko) | 내플라즈마성 부재 | |
| DK3402782T3 (da) | 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decanderivater | |
| BR112015012269A2 (pt) | estrutura modular para expositor de embalagens do tipo torre. | |
| EA202092926A3 (ru) | Лиофилизированные составы, содержащие фактор ix | |
| DK3250216T3 (da) | Immunmodulatorisk sammensætning, som omfatter bifidobakterier | |
| JP2017528459A5 (da) | ||
| ZA201802565B (en) | New adjuvant and vaccine composition containing the same | |
| JP2016047837A5 (da) | ||
| JP2015043197A5 (da) | ||
| JP2016054715A5 (da) | ||
| ITUA20163609A1 (it) | "micro-cogeneratore". | |
| JP2016045189A5 (da) | ||
| JP2015200574A5 (da) |